Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amphastar Pharmaceuticals

29.83
-0.6700-2.20%
Post-market: 29.830.00000.00%16:20 EDT
Volume:374.38K
Turnover:11.17M
Market Cap:1.39B
PE:11.13
High:30.55
Open:30.53
Low:29.47
Close:30.50
52wk High:53.96
52wk Low:20.39
Shares:46.50M
Float Shares:35.34M
Volume Ratio:0.79
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.68
EPS(LYR):3.29
ROE:18.32%
ROA:7.31%
PB:1.83
PE(LYR):9.06

Loading ...

Aug 12, 2025

Major Issues Report

Form 8-K - Current report
Aug 07, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 07, 2025

Major Issues Report

Form 8-K - Current report
Aug 01, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jul 21, 2025

Major Issues Report

Form 8-K - Current report
Jul 03, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 04, 2025

Major Issues Report

Form 8-K - Current report
Jun 02, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 08, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 07, 2025

Major Issues Report

Form 8-K - Current report
May 01, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Apr 01, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 06, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 04, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 04, 2025

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 27, 2025

Major Issues Report

Form 8-K - Current report
Dec 09, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 12, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 12, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 07, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]